The same biology as GLP-1 drugs — activated naturally, without a prescription, a needle, or a $1,000 bill.
GLP-1 drugs built a market and then left a structural gap. More than 50% of patients stop within 12 months. Weight returns. No non-pharmaceutical solution has closed that gap. Until now.
Natural GLP-1 and GIP activation. DPP-4 inhibition. 13 validated metabolic pathways. No prescription. No injection.
The preserved incretin signal is the coordinating backbone that enables the downstream network to activate coherently — restoring metabolic signaling fidelity within physiological constraints rather than imposing pharmacologic override. Supported by a reference library of 200+ peer-reviewed publications. Full scientific monograph available upon request.
Our forward-looking pipeline of what's to come.
A platform built for the future of neuroscience.
One platform. Five categories. Same biology across every format — no prescription required.
The flagship product of the NutraGLP® Sync platform. A daily shot delivering GLP-1/GIP incretin amplification with thermogenic activation — launching soon.
GLP pathway activation in a format built for active people. Combines thermogenic activation with incretin-level biology — delivering energy, focus, and fat-burning activation in every serving.
The NutraGLP® platform in its most accessible everyday format. Sweeten your coffee, tea, or food — and activate incretin biology with every use. Zero calories. Zero compromise.
The only protein formula that works with your metabolic biology — not against it. Combines high-protein anabolic support with GLP-1/GIP amplification to preserve and build lean mass while managing weight.
The NutraGLP® core bioactive signaling complex formulated for incorporation into third-party food and beverage brands. The "Intel Inside" model for metabolic health — licensing incretin biology directly into the products people already buy.
A 503-subject observational study compared a licensed NutraGLP® predecessor formulation against published semaglutide and tirzepatide data — demonstrating significant weight loss with a fraction of the adverse effects.
| Duration | NutraGLP® | Semaglutide | Tirzepatide |
|---|---|---|---|
| 3 Months | 7.3% | 3.6% | 5.9% |
| 6 Months | 14.1% | 5.8% | 10.1% |
Study Disclosure
Observational cohort, n=503, six months, real-world conditions. Not a randomized controlled trial. No control group. Results are hypothesis-generating and should not be interpreted as proof of causation. Individual results will vary.
Adverse events captured via self-report — this method undercounts relative to clinical trial monitoring. Comparisons to semaglutide and tirzepatide drug data (Rodriguez et al., JAMA Internal Medicine, 2024) are for context only and are not head-to-head comparisons. Drug comparison data uses more rigorous collection methods. Weight loss comparisons are drawn from independent published literature, not a parallel controlled study.
A placebo-controlled randomized trial is planned. Nothing here constitutes a medical claim or FDA-evaluated evidence. NutraGLP® products are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider before starting any weight management program.
NutraGLP® Sync fills the gap between pharmaceutical GLP-1 drugs and conventional supplements — incretin-level biology without the drug, the needle, or the prescription.
Same results. A fraction of the side effects. One-tenth of the cost.
| NutraGLP® Slim SHOT | Semaglutide | Tirzepatide | |
|---|---|---|---|
| Monthly Cost | $145 | $900 – $1,100 | $1,000 – $1,300 |
| Delivery Format | Oral — nanoemulsion | Weekly injection | Weekly injection |
| Prescription Required | No | Yes | Yes |
| Adverse Effect Rate | <5% (all mild) | >80% (mild to severe) | >80% (mild to severe) |
| Avg. Weight Loss (6 mo.) | 14.1%* | 5.8% | 10.1% |
| Muscle / Collagen Loss | Not observed | Documented | Documented |
| DPP-4 Inhibition | Yes — core mechanism | No | No |
| Multi-Pathway Coordination | 13 validated targets | Single receptor axis | Dual receptor axis |
*Observational cohort, n=503. Non-randomized. Not a head-to-head comparison. Controlled trial planned.
NutraGLP® patents protect a method, not a formulation. Compositions, signaling pathways, delivery systems, and product forms create layered protections — all must be circumvented simultaneously.
No doctor visit. No pharmacy. Ships directly to you.
GRAS-certified. No FDA drug approval required. Compliance is built into the platform. While compounded GLP-1s face escalating enforcement, NutraGLP® operates entirely outside that exposure.
GLP-1 drugs created the demand. NutraGLP® meets it — no prescription, needle, or $1,000 bill.
Four decades. One pattern: identify the mechanism before the market does, build the science, create the category. NutraGLP® is that work applied to weight loss.
NutraGLP® Biosciences is the same pattern applied to the largest opportunity of his career.
Be first when Slim SHOT launches — join the list below.
Investors & partners: documentation available upon request.
Sign up to receive early updates, key announcements, exclusive insights, and special offers from our company. Join our mailing list to stay informed from the very beginning.
NutraGLP® Biosciences is building the next category in metabolic health. Executive summary, scientific monograph, and clinical documentation available to qualified strategic and investment partners upon request.